Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

Gastrointestinal tumours, non-colorectal 2

3209 - Health-related Quality of Life (HRQOL) and Disease Symptoms in Patients With Unresectable Hepatocellular Carcinoma (HCC) Treated With Lenvatinib (LEN) or Sorafenib (SOR)

Date

10 Sep 2017

Session

Gastrointestinal tumours, non-colorectal 2

Presenters

Arndt Vogel

Citation

Annals of Oncology (2017) 28 (suppl_5): v209-v268. 10.1093/annonc/mdx369

Authors

A. Vogel1, S. Qin2, M. Kudo3, S. Hudgens4, T. Yamashita5, J. Yoon6, L. Fartoux7, K. Simon8, C. López López9, M. Sung10, C. Dutcus11, S. Kraljevic12, T. Tamai11, N. Grunow4, G. Meier11, V. Breder13

Author affiliations

  • 1 Department Of Gastroenterology, Hepatology And Endocrinology, Hannover Medical School, 30625 - Hannover/DE
  • 2 Department Of Medical Oncology, Nanjing Bayi Hospital, 210002 - Nanjing/CN
  • 3 Faculty Of Medicine, Kindai University Faculty of Medicine, Osaka/JP
  • 4 Clinical Outcome, Solutions, 85719 - Tucson/US
  • 5 Department Of Gastroenterology, Kanazawa University Hospital, 920-8641 - Kanazawa/JP
  • 6 Department Of Internal Medicine, Seoul National University Hospital, Seoul/KR
  • 7 Oncology, Hopital Saint-Antoine, Paris/FR
  • 8 Nzoz Centrum, Badan Klinicznych, Wroclaw/PL
  • 9 Department Of Medicine, Hospital Universitario Marqués de Valdecilla, Santander/ES
  • 10 Department Of Oncology, Tisch Cancer Institute at Mount Sinai, New York/US
  • 11 Eisai, Inc., NJ 07677 - Woodcliff Lake/US
  • 12 Eisai Co., Ltd, Hatfield/GB
  • 13 Department Of Oncology, FSBSI N. N. Blokhin Russian Cancer Research Center, Moscow/RU
More

Resources

Abstract 3209

Background

A recent phase 3, randomized, open-label, noninferiority trial compared the efficacy and safety of LEN to SOR as first-line systemic treatment in unresectable HCC (954 patients). The study included analyses to evaluate the impact of therapy for HCC on HRQOL.

Methods

HRQOL was assessed using the European Organization for Research and Treatment of Cancer Quality-of-Life Questionnaire (EORTC QLQ-C30), the HCC-specific module (EORTC QLQ-HCC18), and the European Quality of Life (EQ-5D-3L) at baseline, Day 1 of each cycle, and off-treatment visit. Changes from baseline in both treatment arms were assessed using linear-mixed models with selected covariates (baseline score, geographical region, macroscopic portal vein invasion and/or extrahepatic spread, ECOG-PS, body weight). Time to worsening for each domain was represented as months to deterioration defined by a minimally important difference (MID).

Results

A total of 954 patients (LEN treatment n = 478; SOR treatment n = 476) were randomized and included in the intent-to-treat population. Baseline HRQOL scores were similar for patients receiving LEN or SOR across all domains. Significant changes from baseline HRQOL scores were noted for Nutrition, Diarrhea, Role Function (RF), Pain, and Body Image (BI). In the QLQ-HCC18 Nutrition domain, lower adjusted mean scores in favor of LEN were reported at most time points with significant differences at Cycle 6 and Cycle 9 (p 

Conclusions

Most domains met the noninferiority assumption between LEN and SOR. The additional evidence of significant HRQOL benefits further support LEN in terms of functional deterioration delays.

Clinical trial identification

NCT01761266

Legal entity responsible for the study

Eisai Inc

Funding

Eisai Inc

Disclosure

M. Kudo: Honoraria: Bayer, Eisai, MSD, EA Pharma. S. Hudgens: Consultant to Eisai. J-H. Yoon: Research grants from Bayer HealthCare Pharmaceuticals, Daewoong Pharmaceuticals, and Bukwang Pharmaceuticals. C. López López: Grants, personal fees, non-financial support and other from Eisai, Bayer, Lilly, Daiichi Sankyo. C. Dutcus: Employee of Eisai Inc. S. Kraljevic: Employee of Eisai Co Ltd. T. Tamai, G. Meier: Employee of Eisai Inc. V. Breder: Consulting: BMS, MSD, Bayer, Boehringer-Ingelheim. Lectures: BMS, MSD, Bayer, Boehringer-Ingelheim. All other authors have declared no conflicts of interest.

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings
  • Necessary cookies enable core functionality. The website cannot function properly without these cookies, and you can only disable them by changing your browser preferences.